Suzanna Hutt1,2, Anil Tailor1,2, Patricia Ellis1,2, Agnieszka Michael2,3, Simon Butler-Manuel1,2, Jayanta Chatterjee1,2. 1. a Department of Gynaecological Oncology , Royal Surrey County Hospital , Guildford , UK. 2. b Department of Clinical and Experimental Medicine (Oncology Section), School Biosciences and Medicine, Faculty of Health and Medical Sciences, University of Surrey , Guildford , UK. 3. c Department of Medical Oncology , Royal Surrey County Hospital , Guildford , UK.
Abstract
INTRODUCTION: Endometrial cancer is the most common gynaecological cancer and its incidence is rising due to increasing obesity rates. We are also seeing an increasing trend of young women diagnosed with either endometrial cancer or its precancerous state, endometrial hyperplasia. Diagnosis is dependent on invasive testing and there is no screening tool available for either general or high-risk population groups. Whilst vast amounts of research have been undertaken in higher-profile cancers such as ovarian and cervical, endometrial cancer is comparatively less investigated. AIM: In this literature review, we summarise the existing literature in understanding the role of tumour biomarkers for endometrial cancer and its preceding condition of endometrial hyperplasia. METHOD: NICE Healthcare Databases Search tool was used to search Embase, Medline and PubMed databases for relevant articles. CONCLUSION: There is currently no routinely used biomarker in endometrial cancer for diagnostic or prognostic purposes. Given the establishment of new genomic classifications of endometrial cancers, the use of biomarkers to drive therapeutic approaches will be the cornerstone for individualised cancer care in the coming decades.
INTRODUCTION:Endometrial cancer is the most common gynaecological cancer and its incidence is rising due to increasing obesity rates. We are also seeing an increasing trend of young women diagnosed with either endometrial cancer or its precancerous state, endometrial hyperplasia. Diagnosis is dependent on invasive testing and there is no screening tool available for either general or high-risk population groups. Whilst vast amounts of research have been undertaken in higher-profile cancers such as ovarian and cervical, endometrial cancer is comparatively less investigated. AIM: In this literature review, we summarise the existing literature in understanding the role of tumour biomarkers for endometrial cancer and its preceding condition of endometrial hyperplasia. METHOD: NICE Healthcare Databases Search tool was used to search Embase, Medline and PubMed databases for relevant articles. CONCLUSION: There is currently no routinely used biomarker in endometrial cancer for diagnostic or prognostic purposes. Given the establishment of new genomic classifications of endometrial cancers, the use of biomarkers to drive therapeutic approaches will be the cornerstone for individualised cancer care in the coming decades.
Authors: Jingjing Zhu; Tracy A O'Mara; Duo Liu; Veronica Wendy Setiawan; Dylan Glubb; Amanda B Spurdle; Peter A Fasching; Diether Lambrechts; Daniel Buchanan; Pik Fang Kho; Linda S Cook; Christine Friedenreich; James V Lacey; Chu Chen; Nicolas Wentzensen; Immaculata De Vivo; Yan Sun; Jirong Long; Mengmeng Du; Xiao-Ou Shu; Wei Zheng; Lang Wu; Herbert Yu Journal: Cancers (Basel) Date: 2021-04-26 Impact factor: 6.639
Authors: Zvi Yaari; Yoona Yang; Elana Apfelbaum; Christian Cupo; Alex H Settle; Quinlan Cullen; Winson Cai; Kara Long Roche; Douglas A Levine; Martin Fleisher; Lakshmi Ramanathan; Ming Zheng; Anand Jagota; Daniel A Heller Journal: Sci Adv Date: 2021-11-19 Impact factor: 14.136
Authors: Gulzhanat Aimagambetova; Sanja Terzic; Antonio Simone Laganà; Gauri Bapayeva; Philip la Fleur; Milan Terzic Journal: J Clin Med Date: 2021-12-30 Impact factor: 4.241